home homepresentersregisterrequest one on one conference
Israeli Life Sciences Roadshow 2005

About Our
Presenting
Companies

Atox Bio
Biological Signal Processing
BioMas
Cardioinspect
Core Dynamics
Diagnostic Technologies
Flowmedic
Immunomed
Izun Pharmaceuticals
Nicast
Optimata
Paieon
Solubest
Tagra
V-Target


Events

Monday, April 18
Maryland

Johns Hopkins University
A & R Building
9601 Medical Center Drive
Rockville, Maryland

Tuesday, April 19
New Jersey

IDT Corporate Office
Newark, NJ

Wednesday, April 20
New York

55 Broad Street
5th floor
New York, NY

Thursday, April 21
Massachussetts

Northeastern University
Boston, MA

Overview

Ehud Olmert

Dear Friends,

The Israeli biotechnology industry is a world pioneer in research and development and the Ministry of Industry, Trade and Labor is an eager and encouraging partner of the ever-expanding number of Israeli companies involved in ground-breaking biotechnological activities.

The statistics are amazing; Israel biotechnology sales have increased from USD $15 million in 1988 to USD $2 billion last year. The number of Israeli biotechnology companies has grown from just four companies in 1980 to over 200 in 2003 and includes some of the world's leading firms. Though Israel is just a tiny country, it represents 2.5% of world biotech sales, has many manufacturing plants devoted to manufacturing biopharmaceutical products.

The main keys to the success and potential of the Israeli biotechnology industry are a strong academic research base and enthusiastic governmental support. Thirty-five percent of Israel's civilian research activities are devoted to life sciences and the country has at least ten research institutes that are heavily invest significant resourcesed in R&D in biotech and related fields.

Israeli researchers are involved in cutting-edge biotech research in fields such as stem cells, genetic engineering and drug development.

The Ministry of Industry, Trade and Labor, along with the Office of the Chief Scientist supports, encourages and invests in young companies through technological incubators and by providing pre-seed funding at the early research stage through a variety of programs.

With such a strong base, I believe that the Israeli biotechnology industry will continue to go from strength to strength, making it an ideal investment opportunity for the long-term. The emphasis in our industry on biotherapeutics especially in the fields of neurology disorders, cancer prevention and cure, and autoimmune system disorders is in line with the fastest growing markets in the world.

I invite you to become our partner in this exciting industry and together we can reach new successes that will benefit both Israel and the world.


Sincerely,
Ehud Olmert
Ehud Olmert